Related Experiment Video
Updated: Jul 2, 2026

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
Published on: June 15, 2018
Primary progressive myoclonus of aging
Maria Alvarez1, John N Caviness
1Department of Neurology, Wilford Hall Medical Center, San Antonio, Texas, USA.
Abstract:
Myoclonus in older individuals usually occurs in the context of associated neurologic features which allow the diagnosis of the underlying disorder. We encountered 7 patients with a newly recognized myoclonus syndrome; we use the term primary progressive myoclonus of aging (PPMA) for this syndrome. Our purpose was to characterize the clinical and electrophysiological properties of this syndrome. Our database was searched for the presence of "myoclonus" in the physical examination. Medical records and laboratory data were retrospectively reviewed, including electrophysiology data. We applied our criteria for PPMA: (1) asymmetric symptomatic action myoclonus, (2) >/=65 years of age, (3) cortical myoclonus physiology, (4) no dementia, (5) no associated features of defined neurodegenerative disorders, and (6) no secondary cause found. Seven patients fulfilled criteria. Age at presentation ranged from 70 to 87 years. Mean duration from myoclonus onset to last follow-up was 2.9 years. Electrophysiology showed positive-negative back-averaged transients, consistent with cortical myoclonus. No patient demonstrated dementia. Brain imaging in all cases was unremarkable. PPMA is a unique syndrome with characteristic findings that differentiate it from dementias and defined neurodegenerative syndromes. It is important to distinguish primary PPMA from other syndromes seen in older individuals to avoid diagnostic confusion. Some cases showed a response to levetiracetam.
Related Concept Videos
Myasthenia Gravis ll: Pathophysiology
Alterations in Muscle Tone lll
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview
Alterations in Muscle Tone ll

